Literature DB >> 7795049

High-level resistance to aminoglycosides: comparison of community and nosocomial fecal isolates of enterococci.

T M Coque1, R C Arduino, B E Murray.   

Abstract

Fecal carriage of enterococci highly resistant to streptomycin, gentamicin, and kanamycin was examined in 64 healthy volunteers with no exposure to hospitals and in 53 hospitalized individuals. High-level resistance to streptomycin and gentamicin was found in fecal specimens from 3% and 0, respectively, of the healthy volunteers and in fecal specimens from 41% and 15%, respectively, of the hospitalized individuals. We found that high-level resistance to kanamycin was also more common among hospitalized individuals than among healthy volunteers (36% vs. 17%). The frequent occurrence of high-level resistance to kanamycin in fecal isolates confirms that amikacin is a poor choice when attempting to achieve synergistic therapy for enterococcal infections, in particular for those infections that are nosocomially acquired.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795049     DOI: 10.1093/clinids/20.4.1048

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

1.  Construction of improved temperature-sensitive and mobilizable vectors and their use for constructing mutations in the adhesin-encoding acm gene of poorly transformable clinical Enterococcus faecium strains.

Authors:  Sreedhar R Nallapareddy; Kavindra V Singh; Barbara E Murray
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

2.  Activity of HMR 3647 compared to those of six compounds against 235 strains of Enterococcus faecalis.

Authors:  D B Hoellman; G Lin; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Activities and time-kill studies of selected penicillins, beta-lactamase inhibitor combinations, and glycopeptides against Enterococcus faecalis.

Authors:  D B Hoellman; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

4.  Molecular characterization of gentamicin-resistant Enterococci in the United States: evidence of spread from animals to humans through food.

Authors:  S M Donabedian; L A Thal; E Hershberger; M B Perri; J W Chow; P Bartlett; R Jones; K Joyce; S Rossiter; K Gay; J Johnson; C Mackinson; E Debess; J Madden; F Angulo; M J Zervos
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

5.  Characterization of antimicrobial resistance in enterococci of animal origin.

Authors:  L A Thal; J W Chow; R Mahayni; H Bonilla; M B Perri; S A Donabedian; J Silverman; S Taber; M J Zervos
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

6.  A novel gentamicin resistance gene in Enterococcus.

Authors:  J W Chow; M J Zervos; S A Lerner; L A Thal; S M Donabedian; D D Jaworski; S Tsai; K J Shaw; D B Clewell
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

7.  Efficacy of ampicillin plus arbekacin in experimental rabbit endocarditis caused by an Enterococcus faecalis strain with high-level gentamicin resistance.

Authors:  V Kak; S M Donabedian; M J Zervos; R Kariyama; H Kumon; J W Chow
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

8.  Antimicrobial resistance in enterococci isolated from Turkey flocks fed virginiamycin.

Authors:  L A Welton; L A Thal; M B Perri; S Donabedian; J McMahon; J W Chow; M J Zervos
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

Review 9.  Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications.

Authors:  L C McDonald; M J Kuehnert; F C Tenover; W R Jarvis
Journal:  Emerg Infect Dis       Date:  1997 Jul-Sep       Impact factor: 6.883

10.  Molecular analysis of glycopeptide-resistant Enterococcus faecium isolates collected from Michigan hospitals over a 6-year period.

Authors:  L Thal; S Donabedian; B Robinson-Dunn; J W Chow; L Dembry; D B Clewell; D Alshab; M J Zervos
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.